The Valley Desk

NCT07484139 · Interventional trial

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

Overall registry status Recruiting

Phase 2

Conditions Head and Neck Cancer, Oral Cavity Squamous Cell Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov